STAT3 and breast carcinoma: In breast cancer cases, HDACis can inhibit metastasis and growth through the IL - 6/STAT3 signaling pathway, while AR antagonists can enhance the antitumor effects of PARP inhibitors in AR-positive breast cancer by regulating the DNA damage response [17, 18].